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The pharmaceutical industry is currently facing multiple challenges, in particular the low number of new
drug approvals in spite of the high level of R&D investment. In order to improve target selection and
assess properly the clinical hypothesis, it is important to start building an integrated drug discovery
approach during Lead Generation. This should include special emphasis on evaluating target engagement
in the target tissue and linking preclinical to clinical readouts. In this review, we would like to illustrate
several strategies and technologies for assessing target engagement and the value of its application to
medicinal chemistry efforts.
 2015 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Great attention has been dedicated in the past few years to
analysis of the current challenges in the pharmaceutical industry.
In spite of the sequencing of the human genome and the exponen-
tial rate of learning in the area of human health, no signiﬁcant
improvements in clinical success rate have been realized. Multiple
authors have analyzed the underlying causes for this inefﬁciency
trend. Many concluded that a lack of efﬁcacy in Phase 2 clinical
studies was the major reason for failure.1–3 The inability of preclin-
ical disease models to predict clinical outcomes and the frequent
irreproducibility of literature ﬁndings further increases the difﬁ-
culty of modern drug discovery.4,5 To both internal and external
observers, it is clear the pharmaceutical industry is in a state of
paradigm shift. The industry is moving away from older strategies
and business models for selecting targets and molecules for clinical
investigation. Recent strategies focus more on developing a deeper
understanding of mechanisms of action, pathway biology, and the
relation of a biological target to human disease. To increase the
probability of technical success, it is crucial to start investing dur-
ing preclinical research in target validation, target selection, and
development of integrated drug discovery strategies.2,6
Identifying potential clinical readouts or biomarkers that can be
used pre-clinically should help connect discovery research (from
hit identiﬁcation to candidate selection) to the ultimate test of
the clinical hypothesis in man. At minimum, being able to demon-
strate sufﬁcient clinical target engagement at the site of actionwould unequivocally establish the validity of a given target for a
speciﬁc disease indication.7
This concept is supported by recent analyses conducted by
major pharmaceutical companies. A retrospective analysis by Pﬁz-
er of 44 drug programs in Phase 2 identiﬁed ‘lack of efﬁcacy’ as the
most common cause of attrition in their discovery programs.8 To
improve drug discovery effectiveness, the authors suggested a
model of ‘three pillars’ for evaluating potential investment in
non-validated drug targets: (1) sufﬁcient exposure of ligands at
the site of action; (2) proof of target engagement; (3) expression
of functional pharmacological activity. The authors’ conclusion
was that projects being able to demonstrate all ‘three pillars of sur-
vival’ should have the highest probability of translating in human
clinical studies.
AstraZeneca has also recently published an exhaustive review
of their small molecule pipeline from 2005 to 2010.9 They identi-
ﬁed ﬁve critical technical determinants of project success (coined
the ‘ﬁve R’s’): the right target, the right patient, the right tissue,
the right safety and the right commercial potential. In particular,
the ‘right tissue’ is deﬁned as the appropriate exposure of the
candidate drug in the target organ leading to sufﬁcient pharmaco-
logical activity. To assess the ‘right tissue’, it is necessary to eval-
uate pharmacokinetic properties and target engagement to
develop an understanding of the PK/PD correlations relative to
the target organ. Interestingly, it was pointed out by the authors
that less than 10% of the projects reviewed had demonstrated a
strong correlation between target occupancy and pharmacological
activity.
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background and discussion on how target engagement can be used
in Lead Generation drug discovery along with a brief overview of
various established methods for its measurement. In the second
half, we explore speciﬁc examples from recent literature where
target engagement is being interrogated within Lead Generation
and highlight emerging technologies that can assess target
engagement.
Target engagement in Lead Generation: Traditionally, drug dis-
covery teams build a testing scheme progressing compounds from
in vitro testing (to measure binding, afﬁnity, and selectivity) to
assessing ADMET properties and efﬁcacy in preclinical animal
models.10–12 A target engagement assay (Fig. 1) linking compound
performance in vitro to compound performance in vivo is critical to
ensure the appropriate compound concentration reached the
intended target. Ideally, an integrated discovery approach will link
target engagement with relevant clinical endpoints. It is important
to emphasize that there are different types of biomarkers: (1) diag-
nostic markers, to assess the presence or absence of disease; (2)
disease activity markers, to assess severity of the disease; (3) drug
effect biomarkers, markers of target engagement and PD effects;
(4) drug kinetic biomarkers, to assess genetic variants on drug
metabolizing enzymes and drug transporters. For the purpose of
this review, we will refer to drug effect biomarkers.
An excellent example of the use of drug effect biomarkers is the
development of sitagliptin, a DPP4 inhibitor for the treatment of
diabetes. Preclinical studies demonstrated that 80% inhibition of
the enzyme generated maximal lowering of blood glucose. Similar
degrees of DPP4 inhibition in the ﬁrst human studies were associ-
ated with reduced glucose levels. Those correlations signiﬁcantly
facilitated Phase 2 clinical studies, and even shortened clinical
development time.13 A second example where target engagement
has been clearly linked to efﬁcacy is anti-psychotic drugs targeting
the dopamine D2 receptor. It is now well established that achiev-
ing 60% receptor occupancy correlates to positive beneﬁts in
patients.14,15
Being able to assess the degree of target engagement, pharma-
codynamics and duration of effect (time on target) relative to pre-
clinical measures of efﬁcacy (e.g., behavioral measures,
biomarkers, etc.) are crucial for compound selection and further
hypothesis generation (Fig. 2). Once the correlation is built
between in vitro activity, target engagement and in vivo efﬁcacy,
a target engagement assay should supply a mechanism for rapid
decision making. Such an approach has the potential to require less
use of iterative preclinical animal models, which supports the
responsible use of animals for research.16,17
There is a wide variety of methods to measure target engage-
ment biomarkers. The use of a particular method is inﬂuenced by
the ease of access to the relevant tissue and the nature of the
downstream pharmacological effect.18 For example, within theFigure 1. Flowscheme representation: building correlations across the drug discovery
There should be a connection between preclinical and clinical readouts. Clinical resu
correlations along the drug discovery paradigm.ﬁeld of chemical biology, Cravatt and co-workers have highlighted
the use of chemical probes to engage their intended targets in vivo
to validate protein function.19 Optimized functional chemical
probes can measure occupancy inside the cell and facilitate unbi-
ased selectivity determination in a more physiologically relevant
environment.
Imaging techniques like positron emission tomography (PET)
have received great attention since they can enable non-invasive
target engagement assays compatible with human clinical stud-
ies.20,21 Recent developments in liquid chromatography coupled
to tandem mass spectrometry (LC–MS/MS) methods, have enabled
the rapid assessment of chemical space for a suitable tracer in a
preclinical setting.22 It takes advantage of the same biology that
PET measures by comparing levels of the tracer in a total binding
region to that of a null (target deﬁcient) region, distinguishing spe-
ciﬁc binding from background. Several examples from different
companies applying this methodology to their medicinal chemistry
efforts will be discussed later in this review.
Key breakthrough advances in imaging technology have
allowed for an increase in imaging resolution resulting in a signif-
icant number of applications to early drug discovery. In vivo bio-
luminescent imaging (BLI) is a sensitive tool based on detection of
light emission from cells or tissues. Reporter gene technology
enables the analysis of speciﬁc cellular and biological processes
in a living animal through imaging methods. Combining animal
engineering with molecular imaging techniques, it is possible to
conduct dynamic studies of speciﬁc molecular processes in living
animals. BLI-based models founded on the same reporter assays
used in high-throughput screening (HTS), could offer a bridge
between in vitro biological assays and preclinical animal model
efﬁcacy studies. In comparison with animal models, mechanistic
BLI reporter models require less resources. They also have a
higher throughput and generate quantitative data for compound
ranking in three formats: primary cells, tissues and whole ani-
mals.23 This approach could dramatically impact cycle times dur-
ing Lead Generation efforts. An interesting recent example is the
generation of a bioluminescence transgenic mouse model for
detecting ligand activation of GPCRs by Polites and co-workers
at Sanoﬁ.24
Another example of molecular imaging is biodistribution stud-
ies conﬁrming that a compound reaches the target tissue. This also
allows assessment of accumulation in non-target sites. Investiga-
tions in whole-animal imaging using micro-PET have garnered
increased interest. This is due to the technique’s ability to assess
biodistribution not only for CNS targets but also for oncology tar-
gets where up-regulation of pumps excluding drugs from tumors
are a signiﬁcant issue.25–27
Target engagement studies are most valuable when there is a
robust hypothesis regarding the extent of target engagement
needed for a pharmacological effect. In those cases, data relatingparadigm. Blue boxes represent preclinical assays and red boxes clinical readouts.
lts should also inform future discovery projects. Arrows represent critical data
Figure 2. Iterative drug discovery process.
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tion directly. All preclinical drug discovery projects should have a
hypothesis regarding the level and duration of target occupancy
that is anticipated will deliver a desired in vivo outcome. Establish-
ing and testing target engagement-pharmacology hypotheses are
crucial for a project to ultimately select the optimal candidate
molecules.
During Lead Optimization (LO) when additional toxicology data
is available, a target engagement assay can be a very powerful tool
to compare compounds. For example, Figure 3 shows the target
engagement versus plasma compound concentration for two hypo-
thetical compounds A and B which are ligands for target X. In this
instance, it has been hypothesized that achieving a minimum of
60% target engagement is required to deliver the desired pharma-
cological effects (shown as a solid horizontal line on the graph).
However, each molecule also has adverse effects driven by off-
target activity which occur at unique plasma concentrations
(shown as dashed vertical lines). Thus, each compound has a
different margin of safety (MOS, see shaded rectangles).Figure 3. Hypothetical example illustrating how target engagement could help to diff
compound concentration for two structurally-different compounds, A and B, active f
engagement needed to achieve efﬁcacy. Dashed lines represent plasma concentrations
represent margins of safety (MOS) for each compound.Examples of target engagement in Lead Generation: Increasingly,
we are seeing more researchers publishing on, and emphasizing
the importance of the application of target engagement assays to
their medicinal chemistry efforts. In the second part of this review,
we will highlight a few selected examples of these integrated drug
discovery approaches published recently. These examples span the
known range of techniques, strategic approaches, stages of the
drug development lifecycle, target classes, and disease opportuni-
ties. By design, each highlighted biological target has yet to be
either validated (commercial launch) or invalidated (deﬁnitive
clinical experiment) as a human drug target. These are truly ongo-
ing efforts. In some cases, signiﬁcant gaps in knowledge exist
within the published literature. Our hope is that in presenting a
broad overview of how others are approaching the fundamental
questions of target engagement, inspiration will be gained to apply
those learnings. Representative examples cover the following top-
ics: target engagement in the CNS and lung; target engagement in
the periphery; target engagement determination using chemical
methods; target engagement in cells.erentiate compound performance. Graph shows target engagement versus plasma
or the same target (X). Green line represents the hypothesized minimum target
beyond which off-target toxicology is observed for each compound. Shaded areas
Figure 4. The ﬁrst PDE10A clinical candidate PF-02545920 and recently developed
radioligand IMA 107.
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target compartments which can be challenging for drug molecules
to access. The blood brain barrier (BBB) limits exposure of
molecules from the plasma to brain/spinal cord because the cell
junctions of the membrane are much tighter than peripheral mem-
branes.29–34 Further, the presence of multiple efﬂux transporters
within the BBB cells creates additional barriers to compound
delivery.35,36 Additionally, the critical life sustaining functions of
the CNS and the brain’s encapsulation within the skull, effectively
limit the ability to sample brain tissues directly to measure biomark-
ers without euthanizing the lab animal or harming human patients.
CSF can be easily tapped in patients for biomarker assessment. How-
ever, for brain focused targets this can still be an indirect measure of
target engagement depending on the biology in question. Thus, dis-
covery efforts in this arena have sought methods to assess target
engagement through imaging or other indirect methods.
In the case of the lungs, the lung architecture presents unique
challenges for direct delivery of drugs due to its highly branched
structure.37 Efﬁcient delivery of drug to the lung for disease treat-
ment depends on multiple factors such as particle size, density,
shape, velocity, charge, etc. Further the deeper the target is within
the lung, the more difﬁcult it can be to obtain efﬁcient drug deliv-
ery.38 Thus, when a drug is inhaled, determining how much drug is
delivered to the target is important.39 We highlight in this review a
preclinical Itk program that illustrates this challenge.
Phosphodiesterase enzymes: The phosphodiesterases are a family
of enzymes that hydrolyze cyclic phosphate nucleotides (cAMP and
cGMP). The enzymesmake up 11 different families, each containing
multiple isoforms, which are differentially expressed throughout
the tissues of mammals. Because cAMP and cGMP are important
biological signaling molecules and tissue distribution for some
PDEs is speciﬁc, PDE inhibitors have been identiﬁed as potential
drug targets. To date, multiple PDE5 inhibitors have been success-
fully developed for human use in treating erectile dysfunction.
In attempting to validate PDEs as drug targets, several challenges
have been encountered. The ﬁrst is the transient nature of the sub-
strates and the fact that the product nucleosides are also produced
by other non-PDE related pathways. Thus, substrate measurement
rather than product measurement must be used to interrogate the
enzyme reaction in vivo. The second is target location. Several of
the highest interest PDEs (PDE2, PDE9, and PDE10) are found in
the CNS. The third challenge is the high level of homology between
the PDE families and their respective isoforms. The approaches that
have been taken to demonstrate pre-clinical and clinical target
engagement for the PDEs have varied but generally fall into three
distinct camps: (1) estimations using compound tissue concentra-
tion relative to potency as a surrogate; (2) use of tracer molecules;
(3) direct measure of substrate in the target compartment.
PDE10A: PDE10A has been a target of intense interest within the
pharmaceutical industry, initially for the treatment of schizophre-
nia and more recently for Huntington’s disease. In 2009, Pﬁzer
announced the ﬁrst clinical compound, PF-02545920 (also known
as MP-10, Fig. 4).40 Since then, several additional efforts have been
disclosed with up to four compounds in registered clinical trials.41
Pﬁzer selected PF-02545920 for development based on efﬁcacy
and its ability to demonstrate a PD effect (5 fold increase in cGMP)
in the striatum (the major brain area of PDE10 expression) at a low
dose. Thus, they connected tissue PD effects with in vitro potency.
In 2012, Pﬁzer disclosed that PF-02545920 failed to reach its pri-
mary efﬁcacy end-point in a trial with schizophrenia patients
and has since begun to explore the opportunities of developing
PF-02545920 as a treatment for Huntington’s Disease.42
In this example, preclinical activity did not translate to clinical
outcomes. The availability of PDE10 tracers would be valuable to
allow clinical assessment of target engagement to ensure that
the clinical hypothesis had been adequately tested. Notably, Pﬁzerhas initiated its own clinical trial to establish receptor occupancy
of PF-02545920 in humans using PET.41 Several other PDE10 trac-
ers have recently been described in the literature. Among these,
IMA-107 (Fig. 4) from Imanova Ltd has been advanced into humans
and initial human data has been disclosed.43 Janssen pharmaceuti-
cals has also reported a number of potential PET and radioligand
tracers.44–47
In 2014, Amgen disclosed their own clinical PDE10A candidate
1e (Fig. 5).48 Their approach to identiﬁcation of a PDE10A inhibitor
relied on a combination of elements including target occupancy
(TO), efﬁcacy, and preclinical species PK performance. To establish
TO, the Amgen scientists used tracer 2 (Fig. 5) developed using a
LC–MS/MS approach.49 The advantage to the LC–MS/MS approach
was that the team could evaluate multiple potential tracers
in vivo prior to performing the costly radiolabeling. In evaluating
compounds 1a and 1d from their SAR, the Amgen team noted that
within scaffold 1, very small changes had signiﬁcant impact on the
compounds’ ability to engage the target.48 That prompted them to
prepare four other close analogs which were assessed with regard
to their ability to engage the target, elicit efﬁcacy in rat PCPmodels,
and cross-species pharmacokinetic performance. Notably, com-
pounds 1b, 1e, and 1f had strong target engagement and low min-
imum efﬁcacious doses (MED) in the rat PCP model. Ultimately,
compound 1e, had a more attractive cross-species PK performance
leading to its being selected for advancement into the clinic.
The examples cited for PDE10 illustrate a variety of approaches
to exploring a novel target. It is not yet known if PDE10 inhibitors
will be successful for human medicinal use. With the recent avail-
ability of clinically useful tracers, well established pre-clinical tar-
get engagement, and the initiation of clinical trials to determine
Figure 5. Amgen PDE10A clinical candidate 1 and tracer 2.
Figure 6. BAY60-7550 and Janssen pharmaceuticals PDE2A inhibitors.
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PDE10 is a valid drug target for human disease in the near future.41
PDE2A: A recent report on the design of selective PDE2A inhib-
itors from Janssen Pharmaceuticals uses multiple techniques of
establishing in vivo target engagement in the pursuit of pre-clinical
target validation.50 PDE2A has been proposed as a potential target
for CNS disorders affecting memory, learning, and cognition. The
initial pre-clinical in vivo target validation data for PDE2 was gen-
erated with inhibitor Bay 60-7550 (Fig. 6). However, some reports
have also suggested that Bay 60-7550 has poor uptake in the
brain.50 Thus, Janssen set out to ﬁnd a brain penetrant and selec-
tive PDE2A inhibitor.50 Beginning with a non-selective PDE2/10
inhibitor, they optimized potency and selectivity using X-ray struc-
tural data culminating in inhibitor 3. Compound 3 displayed excep-
tional selectivity against other PDE enzymes. It also displayed rapid
uptake into the brain and maintained reasonable brain concentra-
tions for up to 2 h after a 10 mg/kg SC dose. Unbound brain levels
at 1 h were determined to be 67 nM (115 ng/g). The authors used
tritium labeled 3 to establish ex-vivo target engagement in rat
brain slices. Co-administration of the selective PDE10 inhibitor
MP-10 (Fig. 4) showed that 1 h post a 10 mg/kg SC dose, PDE2
occupancy was 80%. Thus, with multiple lines of evidence pre-
dicting compound 3 strongly engages PDE2 in vivo, the authors
measured cGMP levels in rat striatum and hippocampus 1 h post
dose and found that in both regions the substrate levels were
300% the levels of the vehicle controls. In the disclosure, no exper-
iments attempting to link target engagement and PD to relevant
pre-clinical efﬁcacy were described.
Pﬁzer has recently reported on its efforts to develop a PET
ligand for PDE2.51 The authors used a properties focused approach
to design an optimal PET ligand for PDE2. Their approach involved
constructing a database of 62 PET ligands that successfully reached
the clinic and 15 others that failed in late-stage clinical develop-
ment as a negative control. Their analysis led them to conclude
that an optimal range of parameters for PET ligand design for novel
targets could be identiﬁed (see Table 1). The authors then set out to
identify a suitable starting point for PET ligand design using these
parameters. This approach identiﬁed compound 4 as a suitable
lead molecule (Fig. 7).The Pﬁzer team then designed and synthesized seven potential
PET ligands (5–11) by varying the phenyl substitution and/or
Table 1
Pﬁzer’s preferred design/selection parameters for novel CNS PET ligands
Pharmacology Non-speciﬁc binding Brain permeability Desirable physiochemical propertiesa
Brainmax/Kd >10 Fu_brain >0.05 RRCK Papp AB >5  106 cm/s cLogP 6 3; cLogD 6 2
>30–100  selectivity Fu_plasma >0.05 MDR BA/AB 6 2.5 MW 6 360 amu
40 < PSA 6 90
Hydrogen-bond donors 6 0.5
pKa 6 8
a Note: the authors used a previously published multi-parameter method to weight physiochemical properties into a composite score.51 Values for what the authors
indicate are the more desirable ranges of speciﬁc properties are shown in the table rather than the composite scores.
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potency against PDE2. Compound 5 showed good in vivo brain
penetration and was selected for radiolabeled synthesis. Evalua-
tion of [18F]-5 in non-human primates demonstrated the com-
pound had rapid and high uptake in the striatum (high PDE2
expression) and low uptake in the cerebellum (low PDE2 expres-
sion). Further, the binding of [18F]-5 could be blocked with a
non-labeled and speciﬁc PDE2 inhibitor.
PDE2A research is less advanced than that for PDE10. However,
the development of selective inhibitors as well as PET ligands
should facilitate the progression of the science to determine the
validity of the target.
5-HT1A receptor: Recent pharmacology research has shown that
infusion of the 5-HT1A receptor agonist 8-OH-DPAT in rats
decreased the volume threshold for bladder voiding.52–55 Con-
versely, a 5-HT1A antagonist (WAY-100635) has been shown to
reverse these effects.53 These reports led Eisai pharmaceuticals to
explore the effects of their 5-HT1A receptor antagonist E2110
(Fig. 8) as a potential therapy for overactive bladder (OAB).56 To
verify the previous ﬁndings, the Eisai team set out to use micro-
PET technology to establish the level of central receptor occupancy
(RO) required for achieving efﬁcacy in a rat model of OAB. Such a
correlation would hopefully provide assistance to the design of
clinical experiments with drug candidate E2110 in humans. To that
end, [11C] WAY-100635 was used to establish the dose dependence
of E2110 receptor occupancy in rat brains relative to plasma con-
centration. The authors then used this data to establish a model
of plasma compound concentration versus RO. In separate pharma-
cology experiments using two different models (surgical and
chemical) of OAB in rats, the authors established the minimum
efﬁcacious dose of E2110. Based on the plasma levels, the authors
used their PK-RO model to project the minimum RO required to
achieve efﬁcacy (deﬁned as increased intervals between micturi-
tion) in both models which was approximately 60%.
In this example, the authors hypothesized that central occu-
pancy of 5-HT1A quantiﬁed by in vivo micro-PET should be a useful
surrogate biomarker to measure anti-OAB effects. Although mictu-
rition is supposedly regulated by several neurotransmitter path-
ways within the central and peripheral nervous system, their
approach clearly outlines a hypothesis for how to determine effec-
tive doses in preclinical models which might be clinically transfer-
rable. Future clinical studies will ultimately determine the validity
of this approach for OAB treatment.
Itk: IL-2 inducible kinase (Itk) plays an important role in anti-
gen receptor signaling in T cells. Thus, it has been proposed as a
potential drug target for anti-inﬂammatory diseases. Glaxo-
SmithKline has reported on a pre-clinical research effort to iden-
tify Itk inhibitors as potential therapies for asthma.57 Itk as an
asthma target presents an interesting drug discovery challenge
because compounds must be highly potent in cells, selective,
and delivered to the lung. There are >500 kinases and there is a
high structural similarity within the ATP binding site. In addition,
cells contain a high ratio of endogenous ATP to Itk’s Km,app(ATP)(endogenous ATP concentrations are 1–2 mM while Km,app(ATP)
for Itk is 5 lM).58 Therefore, the GSK team chose to pursue
covalent irreversible inhibitors in hopes that they could achieve
high cell potency and selectivity within a molecular framework
that could be delivered to the target in the lung. From their
research, compound 12 emerged as a highly soluble, permeable
and potent Itk inhibitor (Fig. 9). Notably, compound 12 showed
good selectivity over other kinases. Selectivity is driven by its
kinetic proﬁle showing a rapid initial non-covalent binding event
followed by a covalent modiﬁcation of the enzyme Cys-442. The
authors found that Itk had a slow turn-over rate after inactivation
by compound 12 which allowed prolonged cellular inhibition of
the kinase post-dose.
The authors note that the use of animal efﬁcacy models for
asthma may not be predictive of human outcomes. Therefore, to
examine the PD activity of their compounds, the authors developed
a rat model in which the compound was aerosolized and delivered
to the lungs via inhalation (2.3 mg/kg dose was delivered over
20 min). Animals were then sacriﬁced, lungs perfused, and a cell
suspension was prepared. To determine target engagement the
amount of the compound delivered to the target was assessed.
Notably, the lung tissue concentration was found to be 6 lM post
perfusion, but most of the compound was not cell associated. Upon
preparation of a cell suspension the concentration was found to be
much lower (8 nM). The cells were then stimulated with anti-CD3
for 18 h and T cell activation was determined by ﬂow cytometry. In
the event, 12 showed almost complete inhibition of T cell activa-
tion. Based on the low level of compound the authors found to
be delivered to the cells (vide supra), this robust effect was consis-
tent with the slow turnover of Itk as measured in their in vitro
experiments.
Target engagement in the periphery: In drug discovery focused on
the periphery as opposed to the CNS, it can be signiﬁcantly more
common for compound plasma levels to be equivalent or nearly
equivalent to those in the target tissue. Therefore, plasma com-
pound levels or biomarkers can be powerful tools for assessment
of target engagement. Still, some areas of peripheral drug discovery
can derive signiﬁcant beneﬁt from alternative methods for estab-
lishing target engagement. In this section, we highlight recent lit-
erature on a class of enzymes located not just in the periphery,
but within the cell nucleus.
Histone deacetylases (HDACs) are a family of enzymes which
remove acetyl groups from lysines of histones.59 Inhibitors of
HDACs have been approved for human use in the treatment of can-
cers but have also been proposed as drug targets for CNS diseases
as well. The HDAC family contains a large number of isoforms and
has a signiﬁcant substrate scope. Different inhibitor biodistribution
and enzyme selectivity proﬁles would be hypothesized to carry dif-
ferent efﬁcacy and safety beneﬁts/risks. Unfortunately, technolo-
gies to assess HDAC inhibitor biodistribution and action have not
been available until recently.
Wang et al. have recently described HDAC PET ligand 13
(Fig. 10).60 Ligand 13 can be used to explore both CNS and periph-
Figure 9. Itk inhibitor.
Figure 10. HDAC PET ligand.
Figure 7. Pﬁzer PDE2A inhibitors and PET ligands.
Figure 8. 5-HT1A receptor antagonist E2110.
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for HDACs 1, 2, 3, and 6. Notably, ligand 13 had strong uptake in
heart, kidney pancreas, and spleen. This uptake could be blocked
with the broad spectrum HDAC inhibitor SAHA.
Not only is biodistribution in the area of HDAC inhibitors
important but having an understanding of how HDAC inhibitors
affect enzyme action in living systems has also been identiﬁed as
a critical need to advance these epigenetic targets as therapies
for human disease. To that end, Munteanu et al. recently reporteda MALDI MS (Matrix-assisted laser desorption/ionization mass
spec) method that allows the determination of histone acetylation
levels in both cells in vitro and in vivo.61 Cells treated with inhib-
itor could be analyzed whether they were suspended or ﬁxed. The
authors were also able to establish EC50s for compounds using this
technology. This cellular approach could then be extended to use in
mice. Using HDAC inhibitor LBH-589 the authors were able to
quantify, in a time dependent fashion, the level of acetylation on
Histone H4. Further, imaging of tumor cross sections could be
accomplished allowing the use of this technology for histological
assessment of compound action.
These two recent advances set the stage for additional under-
standing of HDACs as targets for human disease. Ligand 13 demon-
strates the ability to develop imaging tools for the assessment of
biodistribution and target engagement of new HDAC inhibitors.
Coupled with the MALDI technology for assessing histone acetyla-
tion levels, with these tools one can begin to attempt to link com-
pound target engagement and in vivo effects.
Target engagement determination using chemical methods: In
some scenarios, facile measurement of biomarkers or the use of
imaging agents to determine target engagement in vivo are
impractical for technical, safety, or cost reasons. In such cases,
alternative strategies to assess ligand–target interaction are
needed. In some of these instances, organic synthesis and
T. B. Durham, M.-J. Blanco / Bioorg. Med. Chem. Lett. 25 (2015) 998–1008 1005medicinal chemistry can be used to develop target speciﬁc agents
to assess ligand-target protein interaction. Such technologies are
often used in chemoproteomics.62,63 When properly developed,
these technologies have the ability to be used all the way from
pre-clinical target validation work to human clinical trials. In this
section, we highlight two recent examples from the ﬁeld of kinases
which demonstrate how these approaches can be used across the
drug discovery spectrum for both peripheral and CNS based
targets.
LRRK2: Leucine-rich repeat kinase-2 (LRRK2) mutations that
increase enzyme activity have been linked to Parkinson’s dis-
ease.64–66 Thus, LRRK2 inhibitors represent potential therapeutic
agents for Parkinson’s disease. LRRK2 is expressed in the CNS and
in the periphery. While numerous substrates have been proposed,
to date, the disease relevant substrate(s) for LRRK2 has not been
conﬁrmed.67–72 The absence of a clear disease relevant substrate
and the fact that LRRK2 is found both peripherally and in the
CNS increases the challenge of pre-clinical target validation and
drug discovery efforts. Novartis recently disclosed their efforts to
ﬁnd brain penetrant, potent, and selective LRRK2 inhibitors
(Fig. 11).73 In order to establish target engagement, the authors
wanted to identify a scaffold which could be cross-linked to a solid
support and used to develop a LRRK2 pull-down assay. The team
began their SAR using the non-selective kinase inhibitor Sunitinib
(Fig. 11). The authors generated a number of analogs. From this set,
compound 16 (Fig. 11) was found to be a highly selective LRRK2
inhibitor. It also contained the requisite attachment site (a primary
amine) to link to a solid support. With a pull-down assay tool com-
pound in hand, they set out to ﬁnd a compound to use in in vivo
studies. Fusion of the pyrrole and transposition of the pendant
amide ultimately led to an SAR that delivered two compounds,
14 and 15, which were selective and had PK properties supporting
brain penetration in mice. Using their pull-down assay, the authors
also showed that compound 14 dose dependently engaged LRRK2
in mouse brain after oral dosing. Hopefully, future research will
help to establish if there is a link between target engagement
and PD effects for this target.Figure 11. LRRKBtk: Bruton’s tyrosine kinase (Btk) is expressed in B cells.
Because Btk activation is a critical element of B cell response to
antigens, Btk has been identiﬁed as a potential therapeutic target
for autoimmune and B-cell malignant diseases.74 Notably, cysteine
481 in Btk is not conserved in many other kinases which opens the
possibility of using irreversible inhibition as a means of achieving
selective inhibition within the broader gene family. To that end,
Celgene developed clinical compound CC-292 as a covalent inhib-
itor of Btk which reacts with C481, inactivating the enzyme
(Fig. 12).74
In order to assess the target engagement of Btk by CC-292, the
researchers developed biotinylated inhibitor CNX-500 (Fig. 12).74
As outlined in Figure 13, CNX-500 could be used to assess target
engagement in both mice and human subjects. After dosing of
CC-292, B cells are isolated from plasma and lysed. Treatment of
the lysate with CNX-500 inactivates any Btk not already covalently
bound to CC-292. The CNX-500 protein adduct is then captured
using streptavidin beads and quantiﬁed using ELISA to establish
the level of target engagement of the treatment group relative to
vehicle controls. The use of CNX-500 allowed the authors to estab-
lish timelines for Btk protein turnover, CC-292 PK–PD relation-
ships, and CC-292 target engagement efﬁcacy relationships in a
collagen induced arthritis model in mice. They also used CNX-
500 to establish the PK–PD relationship of CC-292 in healthy
human volunteers.
Recent efforts to establish target engagement in cells: The estab-
lishment of target engagement at the cellular level is extremely
challenging because there are few established technologies. While
cellular assays can be developed for many targets, the measured
signal in these assays often is an indirect outcome of drug–target
interaction. In some cases, direct measures of function are possible
(i.e., substrate depletion, product formation, etc.) but sometimes
the measured signals are more distant, creating potential uncer-
tainty regarding the link between the observed outcome and the
anticipated target–drug interaction.
A recent approach to assessing target engagement of drugs in
cells has been reported by Molina et al.75,76 The authors refer to2 inhibitors.
Figure 12. Btk inhibitor CC-292 and tool compound CNX-500.
Figure 13. CNX-500 is used to assess engagement of Btk by clinical candidate CC-292.
Figure 14. CETSA allows assessment of target engagement in cells.
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Figure 15. Hypothetical output of a CETSA experiment.
Figure 16. Hypothetical output of an ITDRFCETSA experiment. Compound A engages
the target protein more effectively than compound C. Compound B does not appear
to be able to engage the target protein.
T. B. Durham, M.-J. Blanco / Bioorg. Med. Chem. Lett. 25 (2015) 998–1008 1007their approach as CETSA which stands for cellular thermal shift
assay. This technology leverages the same thermal stability assay
used broadly in structural biology to assess compound binding to
proteins except that, rather than using puriﬁed proteins, it uses cell
lysates. In their approach, cells or animals can be dosed with com-
pound and vehicle (Fig. 14). Cells/tissues are then harvested for
analysis from each group. In CETSA, aliquots of the cells are then
incubated at various temperatures for a given time. The cells are
lysed and the amount of soluble target protein remaining is quan-
tiﬁed and reported as its relative intensity. Because heating the
cells causes native proteins to denature and precipitate, binding
of a ligand shifts the thermal stability curve showing proof of com-
pound and target protein interaction (Fig. 15).Figure 17. Proposed drug discovery paradigmThis approach can be modiﬁed to explore the compound con-
centration effects of binding in an experiment that the authors
refer to as an isothermal dose–response ﬁngerprint CETSA
(ITDRFCETSA). Here the animals or cells are treated with compound
in a dose response experiment. Cells from each dosing group are
harvested and incubated at a set temperature prior to lysing and
soluble protein quantiﬁcation. Plotting the relative intensity of
the soluble protein versus compound concentration allows com-
parison of target engagement effectiveness within a series of com-
pounds. For example, in the hypothetical experiment shown in
Figure 16, compound A engages the target protein more effectively
than compound C. Compound B does not appear to be able to
engage the target protein.
The authors demonstrated the potential value of the approach
by comparing the PARP-1 inhibitors iniparib and olaparib.75 Inipa-
rib failed to meet phase 3 efﬁcacy endpoints while olaparib was
recently approved by the FDA.77,78 Using CETSA and ITDRFCETSA
the authors showed that, within their experimental protocol, inipa-
rib did not engage PARP-1 while olaparib did shift the thermal sta-
bility. Based on these results, they suggest that iniparib acts
through an alternative mechanism to PARP-1.
Drug discovery is currently experiencing a paradigm shift due
to the multiple challenges facing the pharmaceutical industry. It
is important to assess the target engagement of a potential drug
within the target tissue to properly interpret PD effects and
efﬁcacy both pre-clinically and clinically. In this review, we
have exempliﬁed several cases across different indications that
highlight the use of target engagement assays during Lead
Generation.
To capitalize on the beneﬁts of using target engagement tech-
niques along the drug discovery process, it is important to pro-
spectively build an integrated ﬂowscheme (Fig. 17). In early
Lead Generation, foundational work to enable target engagement
assays is critical and should yield improved decision making. For
example, initial investment in tracer identiﬁcation in Lead
Generation could allow target engagement assessment of multi-
ple scaffolds or individual compounds. Moving toward Lead Opti-
mization, quantiﬁcation of target occupancy could provide better
differentiation of toxicity proﬁles as well as guide dose selection.
Ultimately, these data linking target engagement to PD effects
and preclinical efﬁcacy should enhance the design of the clinical
experiment and provide a deﬁnitive target validation answer
earlier.
In summary, the examples from recent literature described in
this review demonstrate the value of target engagement tech-
niques in medicinal chemistry. As the pharmaceutical industry
and drug discovery science evolve, we anticipate that the trend
to incorporate target engagement into early drug discovery will
continue to increase. Hopefully, these efforts will allow the phar-
maceutical industry to improve its overall efﬁciency.incorporating target engagement assays.
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